vs

Side-by-side financial comparison of Dayforce (DAY) and Embecta Corp. (EMBC). Click either name above to swap in a different company.

Dayforce is the larger business by last-quarter revenue ($481.6M vs $261.2M, roughly 1.8× Embecta Corp.). Embecta Corp. runs the higher net margin — 16.9% vs -40.9%, a 57.7% gap on every dollar of revenue. On growth, Dayforce posted the faster year-over-year revenue change (9.5% vs -0.3%). Over the past eight quarters, Dayforce's revenue compounded faster (9.8% CAGR vs -4.6%).

Dayforce, Inc., formerly Ceridian, is an American human resources software and services company.

Embecta Corp. is a global medical technology company focused on diabetes care solutions. It designs, manufactures and distributes a full portfolio of products including insulin pen needles, syringes, infusion set components and related delivery devices, serving patients, healthcare providers and biopharmaceutical partners across North America, Europe, Asia Pacific and other major markets.

DAY vs EMBC — Head-to-Head

Bigger by revenue
DAY
DAY
1.8× larger
DAY
$481.6M
$261.2M
EMBC
Growing faster (revenue YoY)
DAY
DAY
+9.7% gap
DAY
9.5%
-0.3%
EMBC
Higher net margin
EMBC
EMBC
57.7% more per $
EMBC
16.9%
-40.9%
DAY
Faster 2-yr revenue CAGR
DAY
DAY
Annualised
DAY
9.8%
-4.6%
EMBC

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
DAY
DAY
EMBC
EMBC
Revenue
$481.6M
$261.2M
Net Profit
$-196.8M
$44.1M
Gross Margin
61.9%
Operating Margin
6.3%
31.9%
Net Margin
-40.9%
16.9%
Revenue YoY
9.5%
-0.3%
Net Profit YoY
-9940.0%
EPS (diluted)
$-1.23
$0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DAY
DAY
EMBC
EMBC
Q4 25
$261.2M
Q3 25
$481.6M
$264.0M
Q2 25
$464.7M
$295.5M
Q1 25
$481.8M
$259.0M
Q4 24
$465.2M
$261.9M
Q3 24
$440.0M
$286.1M
Q2 24
$423.3M
$272.5M
Q1 24
$431.5M
$287.2M
Net Profit
DAY
DAY
EMBC
EMBC
Q4 25
$44.1M
Q3 25
$-196.8M
$26.4M
Q2 25
$21.3M
$45.5M
Q1 25
$14.9M
$23.5M
Q4 24
$10.8M
$0
Q3 24
$2.0M
$14.6M
Q2 24
$-1.8M
$14.7M
Q1 24
$7.1M
$28.9M
Gross Margin
DAY
DAY
EMBC
EMBC
Q4 25
61.9%
Q3 25
60.0%
Q2 25
66.7%
Q1 25
63.4%
Q4 24
47.0%
60.0%
Q3 24
45.8%
60.7%
Q2 24
44.1%
69.8%
Q1 24
47.6%
64.6%
Operating Margin
DAY
DAY
EMBC
EMBC
Q4 25
31.9%
Q3 25
6.3%
21.4%
Q2 25
9.1%
31.8%
Q1 25
6.4%
24.3%
Q4 24
6.1%
11.0%
Q3 24
4.7%
9.2%
Q2 24
3.3%
20.5%
Q1 24
9.4%
13.6%
Net Margin
DAY
DAY
EMBC
EMBC
Q4 25
16.9%
Q3 25
-40.9%
10.0%
Q2 25
4.6%
15.4%
Q1 25
3.1%
9.1%
Q4 24
2.3%
Q3 24
0.5%
5.1%
Q2 24
-0.4%
5.4%
Q1 24
1.6%
10.1%
EPS (diluted)
DAY
DAY
EMBC
EMBC
Q4 25
$0.74
Q3 25
$-1.23
$0.44
Q2 25
$0.13
$0.78
Q1 25
$0.09
$0.40
Q4 24
$0.07
$0.00
Q3 24
$0.01
$0.24
Q2 24
$-0.01
$0.25
Q1 24
$0.04
$0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DAY
DAY
EMBC
EMBC
Cash + ST InvestmentsLiquidity on hand
$627.6M
$201.3M
Total DebtLower is stronger
$631.1M
Stockholders' EquityBook value
$2.7B
$-613.1M
Total Assets
$8.7B
$1.1B
Debt / EquityLower = less leverage
0.23×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DAY
DAY
EMBC
EMBC
Q4 25
$201.3M
Q3 25
$627.6M
$225.5M
Q2 25
$625.2M
$230.6M
Q1 25
$557.3M
$209.3M
Q4 24
$579.7M
$210.0M
Q3 24
$494.1M
$267.5M
Q2 24
$465.4M
$275.1M
Q1 24
$392.5M
$299.8M
Total Debt
DAY
DAY
EMBC
EMBC
Q4 25
Q3 25
$631.1M
$1.4B
Q2 25
$631.8M
Q1 25
$632.4M
Q4 24
$1.2B
Q3 24
$1.2B
$1.6B
Q2 24
$1.2B
Q1 24
$1.2B
Stockholders' Equity
DAY
DAY
EMBC
EMBC
Q4 25
$-613.1M
Q3 25
$2.7B
$-650.6M
Q2 25
$2.7B
$-669.6M
Q1 25
$2.6B
$-736.2M
Q4 24
$2.5B
$-768.8M
Q3 24
$2.6B
$-738.3M
Q2 24
$2.5B
$-763.7M
Q1 24
$2.4B
$-769.6M
Total Assets
DAY
DAY
EMBC
EMBC
Q4 25
$1.1B
Q3 25
$8.7B
$1.1B
Q2 25
$8.5B
$1.2B
Q1 25
$9.5B
$1.1B
Q4 24
$9.1B
$1.1B
Q3 24
$8.1B
$1.3B
Q2 24
$9.0B
$1.3B
Q1 24
$10.8B
$1.2B
Debt / Equity
DAY
DAY
EMBC
EMBC
Q4 25
Q3 25
0.23×
Q2 25
0.23×
Q1 25
0.24×
Q4 24
0.47×
Q3 24
0.47×
Q2 24
0.49×
Q1 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DAY
DAY
EMBC
EMBC
Operating Cash FlowLast quarter
$31.2M
$17.2M
Free Cash FlowOCF − Capex
$16.6M
FCF MarginFCF / Revenue
6.4%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
0.39×
TTM Free Cash FlowTrailing 4 quarters
$205.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DAY
DAY
EMBC
EMBC
Q4 25
$17.2M
Q3 25
$31.2M
$84.0M
Q2 25
$112.7M
$81.2M
Q1 25
$49.6M
$31.8M
Q4 24
$81.0M
$-5.3M
Q3 24
$91.8M
$26.6M
Q2 24
$99.2M
$-2.1M
Q1 24
$9.1M
$24.3M
Free Cash Flow
DAY
DAY
EMBC
EMBC
Q4 25
$16.6M
Q3 25
$76.7M
Q2 25
$80.8M
Q1 25
$31.7M
Q4 24
$-6.8M
Q3 24
Q2 24
$-11.8M
Q1 24
$20.9M
FCF Margin
DAY
DAY
EMBC
EMBC
Q4 25
6.4%
Q3 25
29.1%
Q2 25
27.3%
Q1 25
12.2%
Q4 24
-2.6%
Q3 24
Q2 24
-4.3%
Q1 24
7.3%
Capex Intensity
DAY
DAY
EMBC
EMBC
Q4 25
0.2%
Q3 25
2.8%
Q2 25
0.1%
Q1 25
0.0%
Q4 24
0.6%
Q3 24
0.0%
Q2 24
3.6%
Q1 24
1.2%
Cash Conversion
DAY
DAY
EMBC
EMBC
Q4 25
0.39×
Q3 25
3.18×
Q2 25
5.29×
1.78×
Q1 25
3.33×
1.35×
Q4 24
7.50×
Q3 24
45.90×
1.82×
Q2 24
-0.14×
Q1 24
1.28×
0.84×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DAY
DAY

Dayforce Recurring$333.0M69%
Cloud And Bureau Professional Services And Other$78.5M16%
Float$42.2M9%
Powerpay Recurring$19.7M4%
Other Recurring$8.2M2%

EMBC
EMBC

Pen Needles$185.5M71%
Safety$37.3M14%
Syringes$30.7M12%
Manufacturing Facility$4.1M2%

Related Comparisons